C07K 14/472
Complement proteins
Official title: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
C07K14/472 (Complement proteins) appears on 242 US grants and 408 published applications in this corpus.
Search patents in C07K- Granted patents
- 242
- Published applications
- 408
- Assignees
- 235
- Inventors
- 795
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 7 | 0 |
| 1998 | 13 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 7 | 3 |
| 2002 | 5 | 8 |
| 2003 | 3 | 12 |
| 2004 | 6 | 13 |
| 2005 | 3 | 12 |
| 2006 | 3 | 13 |
| 2007 | 4 | 8 |
| 2008 | 4 | 11 |
| 2009 | 3 | 11 |
| 2010 | 6 | 10 |
| 2011 | 6 | 10 |
| 2012 | 4 | 8 |
| 2013 | 7 | 18 |
| 2014 | 6 | 10 |
| 2015 | 8 | 22 |
| 2016 | 10 | 17 |
| 2017 | 8 | 13 |
| 2018 | 10 | 17 |
| 2019 | 15 | 29 |
| 2020 | 12 | 21 |
| 2021 | 15 | 25 |
| 2022 | 15 | 22 |
| 2023 | 11 | 25 |
| 2024 | 14 | 31 |
| 2025 | 9 | 19 |
| 2026 | 9 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Complement factor I and complement factor I cofactor, vectors encoding therefor and therapeutic use8 Sep 2026US 12,728,171 B2Novartis Pharmaceuticals UK Limited
- Isolated antigen binding protein binding to a complement protein C5 and a method of detecting thereof16 Jun 2026US 12,655,201 B2Longbio Pharma (Suzhou) Co., Ltd.
- Anti-parasitic immunological compositions9 Jun 2026US 12,648,993 B2Board of Regents of the University of Nebraska
- Compstatin analogues and their medical uses14 Apr 2026US 12,600,749 B2Zp Spv 3 K/S
- Codon-optimised complement factor I10 Mar 2026US 12,570,707 B2Novartis Pharmaceuticals UK Limited
- Sialylated human factor h protein and therapeutic use thereof1 Oct 2026US 2026/0297144 A1eleva GmbH
- Aav variants for treatment of complement disorders17 Sep 2026US 2026/0275378 A14D Molecular Therapeutics Inc.
- Synthesis and structure of high potency rna therapeutics10 Sep 2026US 2026/0265769 A1Arcturus Therapeutics, Inc.
- Factor b inhibitors and uses thereof13 Aug 2026US 2026/0232760 A1The Trustees of the University of Pennsylvania
- Novel and stable compstatin analogues13 Aug 2026US 2026/0234189 A1Boehringer Ingelheim International GmbH
Most cited
By later US patents
- C5-specific antibodies for the treatment of inflammatory diseases205US 6,355,245 B1Alexion Pharmaceuticals, Inc. · 2002
- Synthetic peptide and its uses95US 5,698,449 ANorthwestern University · 1997
- Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis92US 6,074,642 AAlexion Pharmaceuticals, Inc. · 2000
- High affinity nucleic acid ligands of complement system proteins91US 6,140,490 ANeXstar Pharmaceuticals, Inc. · 2000
- Peptides which inhibit complement activation67US 6,319,897 B12001